NEC Bio

#Artificial intelligence (AI) #Immunology / Virology & Vaccines #NEC Bio #Pandemic response

EU project strengthens pandemic preparedness with AI vaccine design

PREPAIR VAC is a Horizon Europe-funded research project aimed at strengthening pandemic preparedness through the application of artificial intelligence (AI) in vaccine design.  NEC Corporation’s NEC OncoImmunity (NOI) will be working alongside several European partners comprising a research consortium.  The four-year research grant beginning in… Read More

#News

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News